Marinus Pharmaceuticals Inc (MRNS) Given Average Recommendation of “Buy” by Analysts

Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have been assigned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $19.67.

A number of research analysts have recently weighed in on MRNS shares. BidaskClub downgraded shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Cantor Fitzgerald reissued a “buy” rating and set a $19.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, August 2nd. Mizuho reissued a “buy” rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, August 2nd. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Finally, Zacks Investment Research raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th.

Shares of Marinus Pharmaceuticals stock traded up $0.07 on Tuesday, reaching $5.46. 1,368,492 shares of the company traded hands, compared to its average volume of 897,204. Marinus Pharmaceuticals has a 52 week low of $3.31 and a 52 week high of $10.54. The company has a market capitalization of $221.27 million, a P/E ratio of -6.83 and a beta of 3.20.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Monday, October 29th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.06). As a group, research analysts expect that Marinus Pharmaceuticals will post -0.88 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its holdings in Marinus Pharmaceuticals by 298.3% in the 3rd quarter. Wells Fargo & Company MN now owns 17,755 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 13,297 shares during the period. Alps Advisors Inc. boosted its holdings in Marinus Pharmaceuticals by 21.9% in the 3rd quarter. Alps Advisors Inc. now owns 71,706 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 12,905 shares during the period. Northern Trust Corp boosted its holdings in Marinus Pharmaceuticals by 625.7% in the 2nd quarter. Northern Trust Corp now owns 386,864 shares of the biopharmaceutical company’s stock worth $2,736,000 after buying an additional 333,555 shares during the period. Bank of New York Mellon Corp boosted its holdings in Marinus Pharmaceuticals by 190.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 69,863 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth approximately $363,000. 63.68% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

See Also: What are the most popular ETFs

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply